Spinal administration

Clinical Pain Management: Chronic Pain, Second Edition

Volumn , Issue , 2008, Pages 284-291

  Grady, Kate ^a   Raphae, Jon ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b BIRMINGHAM CITY UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862015102     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (53)

1. Intrathecal drug delivery for the management of pain and spasticity in adults; recommendations for best clinical practice. London: British Pain Society, April 2007
2. Pert CB, Snyder SH. Opioid receptor: demonstration in nervous tissue. Science. 1973; 179: 1011-14
3. Yaksh TL, Rudy TA. Narcotic analgesia produced by a direct action on the spinal cord. Science. 1976; 192: 1357-8
4. Behar M, Magora F, Olshwang D, Davidson JT. Epidural morphine in treatment of pain. Lancet. 1979; 1: 527-9
5. Wang J, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979; 50: 149-51
6. Gourlay GK, Cherry DA, Cousins MJ. Cephalad migration of morphine in cerebrospinal fluid following lumbar epidural administration in patients with cancer pain. Pain. 1985; 23: 317-26
7. Cousins MJ, Mather LE, Glynn CJ et al. Selective spinal analgesia. Lancet. 1979; 1: 1141-2
8. Dickenson AH. Recent advances in the physiology and pharmacology of pain: plasticity and its implications for clinical analgesia. Journal of Psychopharmacology. 1991; 5: 342-51
9. Penn RD. Central nervous system drug infusion for pain. In: Tindall GT, Cooper PR, Barrow DL (eds). The practice of neurosurgery. Baltimore: Williams and Wilkins, 1996
10. Mueller-Schwefe G, Hassenbusch SJ, Reig E. Costeffectiveness of intrathecal therapy for pain. Neuromodulation. 1999; 2: 77-87
11. Paice JA, Penn RD, Shotts I. Intraspinal morphine for chronic pain: Retrospective multicentre study. Journal of Pain and Symptom Management. 1996; 11: 71-80
12. Raphael JH, Palfrey SM, Rayen A et al. Stability and analgesic efficacy of di-acetyl morphine(diamorphine) compared with morphine in implanted intrathecal pumps in vivo. Neuromodulation. 2004; 7: 197-200
13. Raphael JH, Southall JL, Treharne GJ, Kitas GD. Adverse effects of Intravenous lignocaine therapy in fibromyalgia syndrome. Rheumatology (Oxford). 2003; 42: 185-6
14. Berde CB, Sethna NF, Conrad LS et al. Subarachnoid bupivavacaine analgesia for seven months for a patient with a spinal cord tumour. Anaesthesiology. 1990; 72: 1094-6
15. Dahm P, Nitescu P, Appelgrenb L, Curelaru I. Continuous intrathecal infusion of opioid and bupivacaine in the treatment of refractory pain due to post herpetic neuralgia; a case report. Neuromodulation. 1998; 1: 85-9
16. Krames ES, Lanning RM. Intrathecal infusional analgesia for non-malignant pain: analgesic efficiacy of intrathecal opioid with our without bupivacaine. Journal of Pain and Symptom Management. 1993; 8: 539-48
17. Van Dongen RTM, Crul BJP, Van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clinical Journal of Pain. 1999; 15: 166-72
18. Markham A, Faulds D. Ropivacaine: a review of its pharmacology and therapeutic use in regional anesthesia. Drugs. 1996; 52: 429-49
19. Eisenach JC, De Kock M, Klimscha W. Alpha2-adrenergic agonists for regional anesthesia: a clinical review of clonidine (1984-1995). Anesthesiology. 1996; 85: 655-74
20. Glynn CJ, Jamous MA, Teddy PJ. Cerebrospinal fluid kinetics of epidural clonidine in man. Pain. 1997; 49: 361-7
21. Eisenach JC, Du Pen S, Dubois M et al. The epidural clonidine study group. Epidural clonidine analgesia for intractable cancer pain. Pain. 1995; 61: 391-9
22. Eisenach JC. Three novel spinal analgesics: Clonidine, neostigmine, amitriptyline. Regional Anesthesia. 1996; 21: 81-3
23. van Hilten BJ, van de Beek W-JT, Hoff JI et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. New England Journal of Medicine. 2000; 343: 625-30
24. Hassenbusch SJ, Satterfield WC, Gradert TL et al. Preclinical toxicity study of intrathecal administration of the pain relievers dextrorphan, dextromethorphan, and memantine in the sheep model. Neuromodulation. 1999; 2: 230-40
25. Walker SM, Goudas LC, Cousins MJ, Carr DB. Combination spinal analgesic chemotherapy: a systematic review. Anesthesia and Analgesia. 2002; 95: 674-715
26. Malinovsky JM, Cozian A, Lepage JY et al. Ketamine and midazolam neurotoxicity in the rabbit. Anesthesiology. 1991; 75: 91-7
27. Tucker AP, Mezzatesta J, Nadeson R, Goodchild CS. Intrathecal midazolam II: Combination with intrathecal fentanyl for labor pain. Anesthesia and Analgesia. 2004; 98: 1521-7
28. Ballantyne JC, Carwood CM. Comparative efficacy of epidural, subarachnoid and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database of Systematic Reviews. 2005; CD005178
29. Smith TJ, Staats PS, Deer T et al. Implantable drug delivery systems study group. Randomised clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain; impact on pain, drug related toxicity and survival. Journal of Clinical Oncology. 2002; 20: 4040-9
30. Smith TJ, Coyne PJ, Staats PS et al. An implantable drug delivery syatem (IDSS) for refractory cancer pain provides sustained pain control, less drug related toxicity and possibly better survival compared with comprehensive medical management (CMM). Annals of Oncology. 2005; 16: 825-33
31. Smith TJ, Coyne PJ. Implantable drug delivery systems (IDSS) after failure of comprehensive medical management (CMM) can palliate symptoms in the refractory cancer pain patients. Journal of Palliative Medicine. 2005; 8: 736-42
32. Hamra JG, Yaksh TL. Equianalgesic doses of subcutaneous but not intrathecal morphine alter phenotypic expression of cell surface markers and mitogen induced proliferation in rat lymphocytes. Anesthesiology. 1996; 85: 355-65
33. Staats P, Yearwood T, Charapata SG et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. Journal of the American Medical Association. 2004; 291: 63-70
34. Raphael JH, Gnanadurai TV, Southall JL et al. Placebo controlled single blind study of short term efficacy of spinal morphine in chronic non malignant pain. Regional Anesthesia and Pain Medicine. 2006; 31: 47
35. Anderson VC, Burchiel KJ. A prospective study of long term intrathecal morphine in the management of non malignant pain. Neurosurgery. 1999; 44: 289-300
36. Hassembusch SJ, Stanton-Hicks M, Covington EC et al. Long term intraspinal infusions of opioids in the treatment of neuropathic pain. Journal of Pain and Symptom Management. 1995; 10: 527-43
37. Tutak U, Doleys DM. Intrathecal infusion systems for treatment of chronic low back pain and leg pain of noncancer origin. Southern Medical Journal. 1996; 89: 295-300
38. Winkelmüller M, Winkelmüller W. Long term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant aetiology. Journal of Neurosurgery. 1996; 85: 458-67
39. Wallace MS, Charapata SG, Fisher R. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomised double blind controlled clinical trial. Neuromodulation. 2006; 9: 75-86
40. Rauch RL, Wallace MS, Leong M et al. A randomised, double blind, placebo controlled study of intrathecal ziconotide in adults with severe chronic pain. Journal of Pain and Symptom Management. 2006; 31: 393-406
41. Thimineur MA, Kravitz E, Vodapally MS. Intrathecal opioid treatment for chronic nonmalignant pain; a 3 year prospective study. Pain. 2004; 109: 242-9
42. Penn RD, Savoy SM, Corcos D et al. Intrathecal baclofen for severe spinal spasticity. New England Journal of Medicine. 1989; 320: 1517-21
43. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. Journal of Neurosurgery. 1992; 77: 236-40
44. Ochs G, Struppler A, Myerson B et al. Intrathecal baclofen for long term treatment of spasticity: a multi centre study. Journal of Neurology, Neurosurgery and Psychiatry. 1989; 52: 933-9
45. Lazorthes Y, Sallerin-Caute B, Verdic JC. Chronic intrathecal baclofen administration for the control of severe spasticity. Journal of Neurosurgery. 1990; 72: 393-402
46. Loubser PG, Narayan RK, Sandin KJ et al. Intrathecal baclofen: long term effects on spasticity in spinal cord injury. Paraplegia. 1991; 29: 48-64
47. Coffey RJ, Cahill D, Steers W et al. Intrathecal baclofen for intractable spasticity of spinal origin. Journal of Neurosurgery. 1993; 78: 226-32
48. Southall J, Beddall C, Raphael JH. Cost utility analysis of intrathecal pump implant for chronic non malignant low back pain. Neuromodulation. 2006; 9: 156-7
49. Sampson FC, Hayward A, Evans G et al. Functional benefits and cost/benefit analysis of continuous baclofen for the management of severe spasticity. Journal of Neurosurgery. 2002; 96: 1052-7
50. Grond S, Zech D, Schug SA et al. Validation for the World Health Organisation guidelines for cancer pain relief in the last days or hours of life. Journal of Pain and Symptom Management. 1991; 6: 411-22
51. Zech DFJ, Grond S, Lyon J et al. Validation of the World Health Organisation guidelines for cancer pain relief: a 10 year prospective study. Pain. 1995; 63: 65-76
52. Stjernsward J, Colleau SM, Ventafridda V. The World Health Organisation Cancer Pain and Palliative Care Program: past, present and future. Journal of Pain and Symptom Management. 1996; 12: 65-72
53. Raphael JH, Southall JL, Gnanadurai TV et al. Long term experience with implanted intrathecal systems for failed back syndrome and chronic mechanical back pain. BMC Muskuloskeletal Disorders. 2002; 3: 17-25